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Abbreviations: BAT, Brown adipose tissue; CPT1, Carnitine palmitoyltransferase I; 2-DE, 
Two-dimensional gel electrophoresis; DAG, Diacylglycerol; FA, Fatty acid; FPLD, 
Dunnigan-type familial partial lipodystrophy; HIV, Human immunodeficiency virus; 
HMGB1, High-Mobility Group Box-1 protein; IPA, Ingenuity Pathway Analysis; LMNA, 
Lamin A; LPC, Lysophosphatidylcholine; MAG, Monoacylglycerol; MS, Mass spectrometry; 
SVF, Stromal vascular fraction; TCA, Tricarboxylic acid cycle; TGA, Triacylglycerol; UCP-
1, Uncoupling protein 1. 
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SUMMARY 
Lipodystrophy is a major disease involving severe alterations of adipose tissue distribution 
and metabolism. Mutations in genes encoding the nuclear envelope protein lamin A or its 
processing enzyme, the metalloproteinase Zmpste24, cause diverse human progeroid 
syndromes that are commonly characterized by a selective loss of adipose tissue. Similarly to 
humans, mice deficient in Zmpste24 accumulate prelamin A and display phenotypic features 
of accelerated aging, including lipodystrophy. Herein, we report the proteome and 
phosphoproteome of adipose tissue as well as serum metabolome in lipodystrophy by using 
Zmpste24
-/-
 mice as experimental model. We show that Zmpste24 deficiency enhanced 
lipolysis, fatty acid (FA) biogenesis and β-oxidation as well as decreased FA re-esterification, 
thus pointing to an increased partitioning of FA toward β-oxidation and away from storage 
that likely underlies the observed size reduction of Zmpste24-null adipocytes. Besides the 
mitochondrial proteins related to lipid metabolism, other protein networks related to 
mitochondrial function, including those involved in tricarboxylic acid cycle (TCA) and 
oxidative phosphorylation, were up-regulated in Zmpste24
-/-
 mice. These results, together with 
the observation of an increased mitochondrial response to oxidative stress, support the 
relationship between defective prelamin A processing and mitochondrial dysfunction and 
highlight the relevance of oxidative damage in lipoatrophy and aging. We also show that 
absence of Zmpste24 profoundly alters the processing of the cytoskeletal protein vimentin and 
identify a novel protein dysregulated in lipodystrophy, High-Mobility Group Box-1 Protein 
(HMGB1). Finally, we found several lipid derivates with important roles in energy balance, 
such as Lysophosphatidylcholine (LPC) or 2-arachidonoylglycerol, to be dysregulated in 
Zmpste24
-/-
 serum. Together, our findings in Zmpste24
-/-
 mice may be useful to unveil the 
mechanisms underlying adipose tissue dysfunction and its overall contribution to body 
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homeostasis in progeria and other lipodystrophy syndromes as well as to develop novel 
strategies to prevent or ameliorate these diseases.  
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INTRODUCTION 
 Adipose tissue has emerged as one of the most important organs regulating body 
homeostasis as it serves not only for the storage of energy in the form of triglycerides but it is 
also a source of paracrine and endocrine signals (i.e. adipokines) that influence systemic 
metabolism (1-4). Dysfunction of adipose tissue, as occurs in conditions of excess (obesity) or 
reduced (lipodystrophy) body fat, results in an abnormal management of triglycerides and 
alteration of adipokine secretion, leading to several metabolic disturbances such as insulin 
resistance, dyslipidemia, hepatic steatosis and type 2 diabetes (4-5). Accordingly, much effort 
has been made to elucidate the molecular mechanisms underlying adipose tissue dysfunction 
and its role in the development of metabolic diseases, including the utilization of proteomic 
approaches [reviewed in (6-7)]. Indeed, both the number and quality of adipose tissue 
proteomic studies have notably increased in the last years. Thus, proteome studies have been 
conducted on adipose tissue biopsies from different fat depots (i.e. visceral and subcutaneous 
adipose tissue) (8) as well as on the two fractions comprising adipose tissue, mature 
adipocytes and the stromal vascular fraction (SVF) (9). Isolation of the separate cellular 
components of the latter fraction has also enabled to establish the proteome of adipose-
derived adult stem cells and adipogenesis (10-12). Moreover, novel adipose tissue secreted 
peptides and proteins have been identified using proteomic techniques (6, 13-14) .  
Since obesity is the most prevalent condition affecting adipose tissue function, the vast 
majority of the proteomic studies carried out to date have focused on the molecular 
characterization of adipose tissue from obese human (8, 15), mouse (16-17), or rat (18-19) 
models. Actually, no other pathological states of adipose tissue have been investigated so far 
using proteomic techniques. In this regard, lipodystrophy, which includes a variety of distinct 
syndromes that may be inherited or acquired in origin, is characterized by a generalized or 
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partial lack of adipose tissue [reviewed by (5, 20)]. Inherited lipodystrophies are commonly 
associated to mutations in single genes whereas acquired lipodystrophies develop in patients 
with certain autoimmune diseases and, more often, in HIV-infected patients under 
antiretroviral therapy [reviewed by (5, 21-22)]. 
 The most common genetic disorders of inherited lipodystrophies have been linked to 
mutations in the LMNA gene encoding the nuclear envelope A-type lamins, lamins A and C 
(5). Although these proteins are expressed in nearly all cell types, mutations in LMNA are 
responsible for at least a dozen different disorders with tissue-selective affections and 
collectively referred to as laminopathies, including Dunnigan-type familial partial 
lipodystrophy (FPLD) (23). In addition to a structural role, lamins are also involved in the 
regulation of DNA replication, transcription and repair (24). In the case of adipose tissue, it 
has been suggested that lamins play a role in adipocyte differentiation yet the molecular 
mechanisms responsible for the loss of adipose tissue associated to lamin A/C deficiency are 
not completely understood [reviewed by (5, 24)]. In humans, mutations in the gene encoding 
the zinc metalloproteinase Zmpste24/FACE1, which is involved in the post-translational 
cleavage of carboxy-terminal residues of farnesylated prelamin A to form mature lamin A 
(25) (Fig. 1), cause progeroid syndromes (i.e. restrictive dermopathy and mandibuloacral 
dysplasia) characterized by a generalized loss of fat, especially pronounced in extremities and 
the truncal region (23-24). Similarly to humans, mice lacking Zmpste24 accumulate prelamin 
A and display phenotypic features of progeria including also a generalized lipodystrophy (26), 
as well as substantial changes in circulating plasma levels of several adipokines (27), 
hormones and growth factors (28-29).  
In order to investigate the exact impact of the impairment of prelamin A processing on 
the functioning of adipocytes, we have carried out a proteomic study of adipose tissue from 
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Zmpste24
-/-
 mice.  Our findings indicate that the absence of Zmpste24 enhances mitochondrial 
function, specially TCA cycle and electron transport chain, to such a level that it causes 
oxidative damage. Other metabolic disturbances directly affecting lipid management, such as 
fatty acid (FA) β-oxidation and re-esterification, together with alterations in vimentin 
processing, likely contribute to the lipoatrophic state associated with lamin A-related diseases. 
Finally, serum metabolomics revealed for the first time several markers of lipodystrophy, 
mostly lipid compounds, further supporting the relevance of the dysregulation of lipid 
metabolism in the premature aging phenotype.    
 
EXPERIMENTAL PROCEDURES 
Animals 
Mutant mice deficient in Zmpste24 metalloproteinase have been previously described 
(26). A total of 38 animals have been used for these studies (18 Zmpste24
-/-
 and 20 wild-type 
males). Animal procedures were conducted in accordance with the guidelines of the 
Committee on Animal Experimentation of the University of Oviedo (Oviedo, Spain).  
 
Histological analysis 
For histological analysis, adipose tissue samples from the visceral fat pad obtained 
from 4 Zmpste24
-/-
 and 3 wild-type animals were fixed in 4% paraformaldehyde in PBS and 
stored in 70% ethanol. Fixed tissues were embedded in paraffin by standard procedures. 
Blocks were sectioned (5 µm) and tissues stained with hematoxylin and eosin. The number of 
adipocytes and their mean diameter were determined in 5-µm tissue sections by computer-
assisted image analysis. For each sample, different microscopic fields were analyzed, and at 
least 100 adipocytes were measured.  
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Protein extraction  
For proteomic studies, adipose tissue biopsies from 4 Zmpste24
-/-
 and 4 wild-type 
animals were washed in PBS immediately after removal and directly frozen in liquid nitrogen 
and stored at -80ºC. Samples were processed following a specific protocol previously 
optimized by us for adipose tissue (9). Thus, fat samples were thawed by adding 0.4 ml of 
cold urea/thiourea buffer [7 M urea, 2 M thiourea, 4% CHAPS, 45 mM Tris pH 7.4, 60 mM 
DTT, and complete protease inhibitors (1 tablet/20 ml, Roche, Barcelona, Spain)] 
supplemented with 0.1 mM NaCl, mechanically disrupted and briefly sonicated. Then, they 
were adjusted to 900 µl with lysis buffer (20 mM Tris pH 7.4, 100 mM NaCl, 1% Triton and 
protease inhibitors; Complete, Roche) and incubated for 15 min at 35°C. After cooling on ice 
for 10 min, 100 µl of 0.1 M Tris, pH 7, and 50 mM MgCl2 were added to the homogenates, 
which were then incubated with DNase I (30 U, St. Louis, MO) for 10 min on ice. The 
homogenate was centrifuged (15 min, 10.000g, 4°C) and the aqueous phase between the 
upper lipid phase and lower cellular debris phase was collected. Extensive delipidation was 
accomplished by Tri-n-butylphosphate-acetone-methanol precipitation. Precipitated proteins 
were resuspended in 75 µl of urea/thiourea buffer. After Bradford assay for protein 
quantification, samples were diluted to 7 µg/µl with urea/thiourea buffer and frozen at -20ºC. 
 
Isoelectric focusing and 2D-PAGE  
350 µg (50 µl) of protein from both wild-type and Zmpste24
-/-
 mice, were diluted in 
300 µl of Rehydratation Buffer and 0.8% of 3-10NL IPG buffer (GE Healthcare, Barcelona, 
Spain). Immobilized pH gradient strips (18 cm, pH 3–10 NL) were rehydrated overnight in a 
Ettan IPGPhor 3 System (GE Healthcare) following a stepwise voltage: 300 V for 3 h, linear 
gradient to 1,000 V for 4 h, linear gradient to 8,000 V for 2 h, and 8,000 V until total Vh 
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(40,000) is reached. Strips were equilibrated in SDS Equilibration Buffer [75 mM Tris, pH 
8.8, 6 M urea, 30% glycerol, 2% SDS] containing 2% DTT for 15 min, followed by a 15-min 
wash with equilibration buffer containing 2.5% iodoacetamide. Thereafter, proteins were 
separated on 12% Tris-glycine gels using an Ettan Dalt Six device (GE Healthcare). These 
conditions resolved proteins with a MW higher than 20 kDa. After migration, gels were 
stained with SYPRO Ruby dye and/or 0.1% Coomassie brilliant blue G-250, 10% ammonium 
sulfate, 2% phosphoric acid and 20% methanol. Both stainings gave similar results.  
Staining of phosphoproteins was performed using Pro-Q Diamond stain (Bio-Rad 
Laboratories, Hercules, CA) according to manufacturer’s instructions. 300 µg of adipose 
tissue extracts were set as the minimum protein amount required for a correct identification of 
phosphorylated proteins. Images of gels stained with Coomassie, SYPRO Ruby or Pro-Q 
Diamond were captured with the FX system (Bio-Rad).  
 
MALDI-TOF-MS analysis  
Spots were excised automatically in a ProPic station (Genomic Solutions, Huntingdon, 
UK) and subjected to MS analysis. MALDI-ToF-MS analysis were carried out on a 4800 
MALDI-ToF/ToF Analyzer (Applied Biosystems/ MDS SCIEX, Concord, Ontario, Canada). 
Gel specimens were destained twice (30 min, 37 °C) with 200 mM ammonium 
bicarbonate/40% acetonitrile. Gel pieces dehydrated for 5 min with pure acetonitrile and dried 
out over 4 h were automatically digested with trypsin according to standard protocols in a 
ProGest station (Genomic Solutions). MS and MS/MS analyses of peptides of each sample 
were analyzed in a 4,700 Proteomics Station (Applied Biosystems) in automatic mode. 
Samples were deposited onto MPep Chips pre-spotted with alpha-cyano-4-hydroxy-cinnamic 
acid (Sunyx, Germany) using the thin layer affinity method and analyzed with the following 
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setting: for the MS data, m/z range 800 to 4,000 with an accelerating voltage of 20 kV and 
delayed extraction, peak density of maximum 50 peaks per 200 Da, and minimal S/N ratio of 
10 and maximum peak at 65. Peak lists for MS/MS data sets were generated using the 4000 
Series Explorer (TM) RAC Software, version 3.5.3 (Applied Biosystems/ MDS SCIEX, 
Concord, Ontario, Canada). For the analysis of vimentin isoforms the m/z range was 
increased from 400 to 4,000.  
Peak lists were submitted to Mascot database in order to identify the proteins 
(Database, NCBInr 12012010 [10320603 sequences; 3520860234 residues]; taxonomy, 
Mammalia [757310 sequences]). Analysis was limited to peptides of six or more amino acids 
and maximum one missed cleavage site. Mass tolerance for precursor ions was set to 100 ppm 
and mass tolerance for fragment ions to 0.2 Da; oxidation of methionine was searched as 
variable modification and carbamidomethylation of cysteine was set as fixed modification. 
MS/MS data were also searched against the ENSEMBL Mus musculus database using the 
open source software X!Tandem (http://www.thegpm.org) with similar settings to those 
employed for Mascot. Peptide false discovery rates (FDR) were determined by a target decoy 
approach using a reversed database concatenated to the parent forward database (30). A cutoff 
expectation value of ≤1.0 [significance threshold; expressed as the negative logarithm of E-
value] was chosen for individual MS/MS spectra that resulted in a FDR of ≤1%. Other post-
translational modifications (i.e. phosphorylation) were also investigated using Expasy 
proteomic server (FindMod and Aldente). To determine whether protein carbamylation 
occurred during the preparation of the samples, representative protein extracts from mouse 
adipose tissue were analyzed by High-Performance Liquid Chromatography and Tandem 
Mass spectrometry using LTQ-Orbitrap XL mass spectrometer (Thermo Fisher Scientific 
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Inc.) equipped with a nanoelectrospray ion source (nESI). No carbamylation was detected 
under these conditions (data not shown). 
 
Immunoblotting  
Frozen fat samples from 4 additional wild-type and Zmpste24
-/-
 mice distinct from 
those employed for 2-DE were disrupted in Triton buffer [20 mM Tris pH 7.4, 150 mM NaCl, 
1% Triton and complete protease inhibitor] and incubated in the presence of 30 units of 
DNase I (Sigma) for 15 min on ice. 30-70 µg of protein were loaded on 10% SDS-PAGE and 
transferred to nitrocellulose membranes (Biotrace, Pall, Germany). After Ponceau staining to 
ensure equal sample loading, membranes were blocked for 1 h with 5% dried milk in TTBS 
(TBS buffer with 0.05% Tween-20). Antibodies against peroxiredoxin 3 (PRDX3), prelamin 
A, β-actin, carnitine palmitoyltransferase I (CPT1), uncoupling protein 1 (UCP-1) and 
phosphoenolpyruvate carboxykinase 1 (PCK1) were purchased from Santa-Cruz 
Biotechnology (Heidelberg, Germany). Anti-vimentin antibody was purchased from 
Biomedal SL (Sevilla, Spain) and anti-malic enzyme 1 (ME1) antibody was from Proteintech 
Group, Inc. (Manchester, UK). After overnight incubation at 4 ºC with the corresponding 
primary antibody, membranes were incubated with the appropriate IgG-HRP-conjugated 
secondary antibody. Immunoreactive bands were visualized with an enhanced-
chemiluminescence reagent (Chemiluminescent HRP substrate, Millipore, MA). Optical 
densities of the immunoreactive bands were measured using ImageJ 1.40g analysis software.  
 
ROS determination 
The intracellular reactive oxygen species (ROS) levels were determined using the 2,7’-
dichloroflourescein diacetate (DCF-DA) dye (Sigma). White adipose tissue were extracted 
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from mice and samples were homogenized using PLB (Promega). The lysates were 
centrifuged at 12,000 g for 5 min at 4ºC, and supernatants were collected. Protein 
concentration in the supernatants was evaluated by the bicinchoninic acid technique (BCA 
protein assay kit, Pierce Biotechnology, Rockford, IL). Supernatants (50 µg) were mixed with 
25 µM DCF-DA and then incubated at 37ºC for 30 min in the dark. Fluorescence at 485/535 
was measured using a LS55 PerkinElmer LifeScience spectrofluorometer. Adipose tissue 
samples from at least 4 different animals of each genotype were used for measurement of 
ROS generation. 
 
Serum metabolomics 
Sera from eight Zmpste24
+/+
 and Zmpste24
-/-
 male mice samples were analyzed. A 
global metabolite profiling UPLC
®
-MS methodology was employed, where all endogenous 
metabolite related features, characterized by mass-to-charge ratio m/z and retention time Rt, 
were included in a subsequent multivariate analysis procedure used to study metabolic 
differences between the different groups of samples (31). Where possible, Rt-m/z features 
corresponding to putative biomarkers were later identified. Sample preparation, LC-MS 
system, data processing, multivariate data analysis were performed as described previously 
(32). The top 50 candidate markers resulting from this procedure were selected and subjected 
to additional statistical testing [fold changes and Wilcoxon rank sum (Mann Whitney) test p-
values]. Finally, the following procedures were used in an attempt to identify selected 
markers: a) Mass spectra recorded in the positive and negative ion modes were analyzed to 
determine the most likely parent (as opposed to metal adducts or fragments) ion m/z value and 
b) The exact mass information obtained, corrected to within a 5 ppm error, was checked 
against the ChemSpider
10
 online database, using the subdatabases: KEGG, Lipid Maps and 
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Human Metabolome database. Where possible, hit lists were further reduced by comparison 
of theoretical / measured isotopic patterns. 
 
Data analysis  
2-DE gel analysis was performed by PDQuest software (Bio-Rad), version 8.0. Spot 
volume values were normalized in each gel by dividing the raw quantity of each spot by the 
total volume of all the spots included in the same gel. Other normalizations provided by the 
PDQuest software were also performed with similar results. Data were log transformed to 
meet the requirements of a normal distribution and analyzed with Student’s t-test using the 
statistics tools included in the PDQuest software. Spots which gave significant results 
(P<0.05) were verified visually to exclude artifacts. Furthermore, statistically significant spots 
were re-checked by two-tailed unpaired Student’s t-test after reevaluation of density with 
ImageJ 1.40g software.  
Statistical analysis used SSPS statistical software, version 11.0 for WINDOWS (SSPS 
INC., Chicago, IL). Statistical differences in western blot experiments were assessed by two-
tailed unpaired Student's t-test. Differences were considered significant at P < 0.05. All data 
are expressed as mean ± S.E.M. For further evaluation, proteins identified by the proteomic 
study were analyzed using a pathway analysis software [Ingenuity Pathway Analysis (IPA); 
Ingenuity Systems, Mountain View, CA] to reveal their potential relationships with other 
proteins and/or intracellular pathways. 
 
 
RESULTS 
Reduced adipose tissue in Zmpste24
-/-
 mice 
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 Zmpste24-null mice display a lipodystrophic phenotype characterized by the absence 
of subcutaneous adipose tissue (26). Herein, we have observed that they also suffer from a 
marked reduction of the visceral fat depot (Fig. 2A), which in some cases reached more than a 
6-fold decrease when compared to that observed in their wild-type littermates. This remaining 
fat pad can be easily removed together with the gonads (Fig. 2B). Histological examination of 
hematoxylin-eosin stained sections revealed that visceral adipose tissue from Zmpste24
-/-
 mice 
is composed of small adipocytes (Fig. 2C), which showed almost half the size of those from 
wild-type animals. Specifically, minimum diameters of adipocytes from Zmpste24-null and 
wild-type mice were 11±2.9 and 18±1.0 µm, respectively, which likely contributes to the 
increased number of total adipocytes observed in adipose tissue from Zmpste24
-/-
 mice 
(649.60±83.3 vs. 443.4±28.5 cells/mm
2
 in Zmpste24
-/-
 and wild-type mice, respectively).  
 
Adipose tissue of Zmpste24
-/-
 mice exhibits altered metabolic pathways   
 Our proteomic analysis of visceral adipose tissue allowed for the identification of 
approximately 1,070 spots in a typical two-dimensional gel. Comparative analysis of the 
proteome of adipose tissue from Zmpste24
-/-
 and wild-type mice (four animals per group) 
revealed that 37 proteins were significantly up-regulated in mutant mice while 9 proteins were 
down-regulated (Fig. 3A). A representative spot corresponding to pyruvate dehydrogenase 
beta (spot 31) is highlighted in Fig. 3B in order to show the reproducibility of the observed 
differences between adipose tissue proteomes from the two groups of animals. Differences in 
the proteome of the four different animals analyzed per group were evaluated and average of 
their density was used to elaborate Table 1, where only those proteins with consistent 
differences (P < 0.05) were included. MALDI-TOF identification of the modified proteins 
showed that the majority of the spots corresponded to proteins participating in known 
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metabolic pathways: i) glycolysis (ENO1), ii) Acetyl-CoA synthesis and TCA cycle-related 
proteins (PC, PDHB, PDX, CS, ACO2, LDH3A, DLST, SUCLG2, SDHA, ME1 and MDH), 
iii) pentose phosphate pathway (G6PD, PGD, TKT and TALDO1), iv) fatty acid synthesis 
(FAS and ACLY), v) fatty acid re-esterification (PCK1), vi) β-oxidation of fatty acids 
(ACSL1 and ACADS), vii) lipolysis [triacylglycerol (TAG) lipase -ATGL- or desnutrin], viii) 
the glycerol-3-phosphate shuttle (GPD1 and GPD2), and ix) valine, leucine and isoleucine 
degradation (PCCA, BCATm, HIBADH and HIBCH). Furthermore, several proteins of the 
mitochondrial electron transport chain (NDUFA10, UQCR1 and ATP5B), the mitochondrial 
response to oxidative stress (PRDX3), cytoskeleton (vimentin, gelsolin), and proteins with not 
yet known function in adipose tissue (HMGB1) were also identified. Classical components of 
the serum were also found to be modified in Zmpste24
-/-
 mice (A2M and SERPIN1A).  
 Herein, we have also observed by 2-DE the accumulation of partially processed lamin 
A in Zmpste24-null mice (Fig 4A). MALDI-TOF/TOF analysis of the protein demonstrated 
that the accumulated protein lacks the –aaX (Figs. 4B and C) which is consistent with 
previous findings in Zmpste24
-/-
 fibroblasts (33), thus suggesting that, in addition to 
Zmpste24, other protease(s) (i.e. Rce1) are likely able to carry out this proteolytic step (Fig. 
4B). Furthermore, the identified protein contains the sequence including the second proposed 
cleavage site of Zmpste24 (Figs. 4B and C), indicating that the protein accumulated in mutant 
animals corresponds exclusively to a partially mature form of lamin A (asterisk in Fig. 4B). 
 
Western blot analysis of altered proteins 
Immunoblotting using an antibody against β-actin revealed the existence of significant 
differences in β-actin protein content between Zmpste24-/- and wild-type animals 
(Supplemental Fig. 1A), thus precluding its use as housekeeping gene for quantitative studies. 
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Furthermore, neither GADPH nor tubulin gave consistent results (data not shown). 
Consequently, all the experiments were carried out loading equal amounts of proteins from 
Zmpste24
-/-
 and wild-type mice and values were further normalized against Ponceau staining 
(Supplemental Fig. 1B). 
Several proteins were chosen for validation of the results obtained by 2-DE:  three 
proteins up-regulated (ME1, PRDX3, and HMGB1; Figs. 5A-C) and two down-regulated 
(PCK1 and vimentin; Fig. 5D and Fig. 6, respectively) in Zmpste24
-/-
 mice. These analyses 
revealed that ME1 was 1.5-fold increased in mutant mice (Fig. 5A) and PRDX3 reached a 4-
fold increase (Fig. 5B) in these animals when compared to levels observed in wild-type mice. 
Likewise, HMGB1 protein content was significantly higher in Zmpste24
-/-
 mice (1.8-fold vs. 
wild-type animals; Fig. 5C) whereas PCK1 was diminished in mutant mice (1.9 fold vs. wild-
type animals; Fig. 5D). Data from immunoblot studies on vimentin are discussed below. 
 
Differential processing of vimentin in adipocytes from Zmpste24
-/-
 mice  
Immunoblotting of adipose tissue extracts with the anti-vimentin serum confirmed the 
data obtained by 2-DE on the existence of four distinct immunoreactive bands of 53, 49, 46 
and 43 kDa in mice adipose tissue (Fig. 6A). As observed by the proteomic approach, the 
smaller isoforms of vimentin were down-regulated in adipose tissue from mutant mice, in 
particular those of 46 and 43 kDa (Fig. 6A). Interestingly, these two short isoforms of 
vimentin, together with prelamin A, were identified in the 2-DE experiments as the most 
differentially expressed proteins between Zmpste24
-/-
 and wild-type mice (Table 1). Thus, 46-
kDa and 43-kDa vimentin forms were reduced by 3.3- and 5.5-fold, respectively, in the 
proteome of mutant mice with respect to those observed in wild-type animals (Table 1). These 
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data are largely in accordance with the results obtained by semiquantitative immunoblotting 
(Fig. 6B). 
Although the presence of vimentin isoforms has also been depicted in proteomic 
studies of human subcutaneous adipose tissue (15), their origin is not known and no 
information is yet available as to whether they may arise from alternative splicing or post-
translational processing. To address this issue, we first analyzed vimentin isoforms by 
MALDI-TOF/TOF. The identified proteins correspond to N-terminal truncated variants 
within the region spanning the first 100 amino acid residues of vimentin (Supplemental Fig. 
2). Fig. 6C shows the first N-terminal tryptic peptide identified in each isoform, including 
their predicted molecular weight and isoelectric point. No cleavage was observed at the C-
terminal end since the tryptic product was readily detected in the MALDI mass spectrum of 
all isoforms (Supplemental Fig. 2). 
 
 
Analysis of mitochondrial function in Zmpste24
-/-
 adipose tissue  
Given the finding that two proteins potentially involved in mitochondrial fatty acid β-
oxidation, long-chain acyl-CoA synthetase-1 (ACSL1) and acyl-coenzymeA dehydrogenase, 
short chain (ACADS), were up-regulated in adipose tissue of Zmpste24
-/-
 mice, we 
investigated whether mitochondrial fatty acid import could be also affected in these animals 
by quantifying protein levels of the key enzyme mediating this process, carnitine 
palmitoyltransferase I (CPT1) (34). Western immunoblotting of adipose tissue protein 
extracts revealed that Zmpste24
-/-
 mice did indeed contain significantly higher levels of CPT1 
than wild-type mice (Fig. 7A).   
Since proteomic studies revealed that several proteins of the mitochondrial electron 
transport chain were up-regulated in the adipose tissue of Zmpste24-null mice, including a 
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subunit of the mitochondrial ATP synthase complex, we hypothesized that ATP levels could 
be altered in Zmpste24-null mice. However, ATP content was not significantly modified in 
mutant mice (data not shown). In order to evaluate whether an increase in thermogenesis, via 
induction of uncoupling protein 1 [UCP-1; (35-36)], could occur in Zmpste24-null mice, we 
investigated its expression by western blot. No immunoreactive band for UCP-1 was observed 
in these samples whereas this protein was clearly visible in immunoblots from paired samples 
of brown adipose tissue (Fig. 7B).    
Finally, the increased levels of mitochondrial PRDX3 found in Zmpste24
-/-
 fat 
prompted us to evaluate the occurrence of oxidative damage in the tissue. As shown in Fig. 
7C, ROS levels were significantly enhanced in adipose tissue of Zmpste24
-/-
 mice as 
compared to wild-type animals, indicating that Zmpste24 deficiency increases oxidative 
stress. 
 
Analysis of the phosphoproteome of adipose tissue 
Phosphorylation is a ubiquitous and fundamental reversible, regulatory mechanism 
that enables to modify protein function by altering protein stability, cellular location, substrate 
affinity, complex formation, or activity (37). Herein, together with the analysis of adipose 
tissue from Zmpste24
-/-
 and wild-type mice by 2D-PAGE, we also employed a 
phosphoproteomic approach to establish the phosphorylation fingerprint of adipose tissue 
proteins in the presence or absence of the metalloprotease (Fig 8A). This has enabled us to 
identify, for the first time, six proteins that are regulated in adipose tissue at the post-
translational level: the mitochondrial complex I subunit NDUFA10, the ATP citrate lyase 
(ACLY), the rate-limiting enzyme for triglyceride catabolism in mice, desnutrin (human 
ATGL1), phosphoglucomutase 1 (PGM-1), desmin, and pyruvate dehydrogenase alpha 1 
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(PDHA1). In addition, the potential phosphorylation sites of three of these proteins were also 
identified (Fig. 8B), including three sites already described in PGM-1 (S95, T96 and T115), 
one in desmin (T42), and a novel phosphothreonine residue in desnutrin (T452), which is 
close to the two C-terminal serine residues previously reported to be phosphorylated in this 
protein (38). Finally, three out of the six proteins found to be highly phosphorylated in mouse 
adipose tissue were also identified by 2D-PAGE on the basis of their overexpression in 
mutant animals: NDUFA10, ACLY, and desnutrin (Table 1).  
 
Serum metabolic profile of Zmpste24
-/-
 mice 
Although microscopy and proteomic analysis of adipose tissue of Zmpste24-null mice, 
together with previous data on the occurrence of hepatic steatosis in these animals (27), 
pointed to the inability of adipocytes to properly store lipids, we observed no changes in 
serum FA levels in mutant mice (data not shown). To get further clues about the metabolic 
biomarkers associated to genetic lipodystrophy, we employed a metabolomic strategy.  Serum 
metabolic profiling revealed 32 metabolites up-regulated in Zmpste24
-/-
 mice while 22 were 
found to be down-regulated.  67 % of the identified metabolites corresponded to known 
compounds (Suppl. Table 1). Analysis of the altered metabolites by a software for pathway 
analysis revealed major perturbations in lipid metabolism and oxidative scavenging (Fig. 9). 
Remarkably, most of the down-regulated metabolites corresponded to lysophospholipids and, 
in particular to several molecular species of lysophosphatidylcholine (LPC). Increased levels 
of several steroids including corticosterone (1.9 fold change) and aldosterone (4.4 to 12.9 fold 
change) were also observed in Zmpste24
-/-
 mice, suggestive of alterations in adrenal gland 
function in these animals. Finally, in agreement with previous observations (27), lower levels 
of glucose were found in mutant mice as compared to wild-type animals.  
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DISCUSSION 
 Lipodystrophy is a major disease involving severe alterations of adipose tissue 
distribution and metabolism. Mutations in genes encoding the nuclear protein lamin A or its 
processing enzyme, the metalloproteinase Zmpste24, cause diverse human progeroid 
syndromes and are associated with the development of lipodystrophy. By using mice deficient 
in Zmpste24, we report for the first time the protein fingerprint of lipoatrophy. We 
demonstrate that adipose tissue of Zmpste24
-/-
 mice exhibit marked alterations in key proteins 
involved in lipid management and energy expenditure. This, together with an abnormal 
processing of the cytoskeletal protein vimentin in Zmpste24
-/-
 adipocytes, may underlie the 
lipodystrophic phenotype associated with the loss of functional Zmpste24. 
Microscopic data revealed that Zmpste24
-/-
 mice contained significantly smaller 
adipocytes than wild-type mice, thus indicating an impaired fat storage capacity in these cells. 
Several processes may contribute to decreased TAG accumulation: increased TAG lipolysis, 
decreased FA uptake or synthesis, decreased FA re-esterification and increased FA release or 
oxidation. Our proteomic data support the view that several of these processes may occur in 
Zmpste24-null adipocytes (Fig. 10). Thus, the observed up-regulation of the rate-limiting 
lipolytic enzyme adipose triglyceride lipase (human ATGL/murine desnutrin) (39) in mutant 
mice strongly suggest that TAG lipolysis is enhanced in these animals. Intriguingly, we have 
identified a novel phosphorylation site in desnutrin (T452), which is close to the two C-
terminal region serines previously reported to be phosphorylated in this protein (S406 and 
S430) (38). It has been recently shown that phosphorylation at S406 or S430 is not necessary 
for the hydrolase activity of desnutrin although the C-terminal region appears to be important 
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for TAG hydrolysis (40). Thus, it seems likely that phosphorylation at T452 plays a role in the 
regulation of desnutrin activity.  
One of the most increased proteins in adipose tissue of null mice was fatty acid 
synthase (FAS), an enzyme that plays a central role in de novo FA biogenesis. FAS converts 
acetyl-CoA and malonyl-CoA into palmitate in a process that requires NADPH, which is 
supplied by both the pentose phosphate pathway and the pyruvate cycle (41). Interestingly, 
many of the enzymes participating in these pathways were also enhanced in adipose tissue of 
Zmpste24
-/-
 mice. Taken together, these findings suggest that de novo lipogenesis is increased 
in mutant mice. In this scenario, the bulk of FA synthesized de novo or generated by TAG 
hydrolysis does not seem to be redirected for esterification into TAG in Zmpste24-null 
adipocytes since, besides the aforementioned reduced size of these cells, adipose tissue from 
mutant mice exhibited diminished levels of the key enzyme involved in glyceroneogenesis 
and FA re-esterification in adipocytes, PCK1 (42). In line with these findings, targeted 
ablation of PCK1 expression in white adipose tissue in mice reduced body fat pads and, more 
notably, nearly 25% of the mutant mice were lipodystrophic (43). Likewise, ritonavir, a 
common component of the antiretroviral therapy associated with the development of 
lipodystrophy in HIV patients (38), decreased PCK1 expression in murine 3T3-L1 adipocytes 
(44). Collectively, these observations favour PCK1 as a common player in the development of 
lipodystrophy.  
Impaired FA re-esterification resulting from down-regulation of PCK1 could lead to 
enhanced FA efflux from Zmpste24-null adipocytes and subsequent ectopic deposition of 
lipids. Indeed, Zmpste24-null mice display a clear hepatic steatosis (27). Nevertheless, we 
(data not shown) and others (27) have found that serum FA levels are not elevated in 
Zmpste24-null mice and thus, it is unlikely that FA from adipose tissue contribute to the 
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extensive lipid accumulation observed in mutant mice liver (27). Instead, lack of Zmpste24 
seems to cause a shift within adipocytes towards increased FA utilization and energy 
expenditure. Thus, mutant mice exhibited enhanced levels of two enzymes involved in FA β-
oxidation (ACSL1 and ACADS). These data, which are consistent with the observed 
upregulation of CPT1, the enzyme responsible of FA translocation across the mitochondrial 
membrane (45), support the view that adipocyte shrinkage in mutant mice is due, at least in 
part, to an increased partitioning of FA toward β-oxidation and away from storage as TAG. 
Furthermore, the increased expression of several proteins associated with oxidative 
phosphorylation suggests that adipose tissue metabolism in mutant mice could be remodelled 
toward ATP production, which is rapidly mobilised to sustain the enhanced rate of FA 
synthesis. Notably, expression of UCP-1, normally found only in brown adipose tissue but 
that can be induced in white adipocytes by different stimuli (35-36) was not altered in 
Zmpste24
-/-
 mice thus suggesting that excess energy is not likely dissipated as heat, at least via 
UCP-1. 
Taken together, our results reveal that the lack of Zmpste24 alters mitochondrial 
function and oxidative capacity of adipocytes. Indeed, a total of 21 out of the 37 proteins 
overexpressed in Zmpste24
-/-
 mice corresponded to mitochondrial proteins involved in 
oxidative metabolism. Considering the prominent role of adipose tissue mitochondria in 
lipogenesis and adipogenesis (46), it is reasonable to propose that mitochondrial alterations 
caused by Zmpste24 depletion contribute to the lipoatrophic phenotype of mutant mice. 
Remarkably, antiretroviral treatment of HIV patients which causes severe lipoatrophies, 
altered the expression of genes involved in FA oxidation, TCA cycle and oxidative 
phosphorylation in adipose tissue (47-49). These changes were associated to up-regulation of 
genes involved in oxidative stress (49-50). In particular, HIV antiretroviral protease inhibitors 
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(PIs), which inhibit Zmpste24 activity and lead to prelamin A accumulation (51), induce the 
expression of oxidative stress markers in adipose tissue in a manner comparable to that 
observed in patients with LMNA mutations (52). In accordance with these observations, 
evidence supporting the occurrence of oxidative stress in adipose tissue of Zmpste24
-/-
 mice is 
provided by our findings of increased ROS levels. Taking into account that PRDX3 provides 
a primary antioxidant defense of mitochondrial respiratory chain (53-54), increased ROS 
levels may account for the significant up-regulation of this peroxidase. Taken together, these 
findings evidence the relationship between defective prelamin A processing and oxidative 
stress and highlight the relevance of oxidative damage in the development of lipoatrophy. 
Interestingly, mitochondrial dysfunction and oxidative stress induced by antiretroviral drugs 
or prelamin A accumulation have been proposed to promote premature cellular senescence of 
preadipocytes (52). Our data on Zmpste24
-/-
 mice, which exhibit clear features of accelerated 
senescence, reinforce the notion of a functional link between defective lamin A maturation, 
mitochondrial alterations and premature aging (55). Notably, Zmpste24 also altered normal 
processing of the cytoskeletal protein vimentin, an intermediate filament that has been 
suggested to regulate mitochondrial function by mediating the interaction of mitochondria 
with microtubules (56). In addition, vimentin has a prominent role in the development of lipid 
droplets during adipocyte differentiation (57-58) and in the control of lipid metabolism in 
differentiated adipocytes (59) and, consequently, the presence of vimentin variants may be 
necessary to provide plasticity to the adipocyte for correct lipid management.  
Our proteomic analysis has enabled the identification of a novel protein dysregulated 
in Zmpste24
-/-
 mice, HMGB1, whose expression in adipose tissue has not been documented 
previously. HMGB1 is a chromatin-binding nuclear protein implicated in DNA repair 
mechanisms (60), and has been also proposed to play a role in sustaining autophagy (61). 
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Notably, previous studies have demonstrated that Zmpste24
-/-
 mice exhibit an extensive basal 
activation of autophagy, which primarily represents a pro-survival mechanism, in liver, 
skeletal muscle and heart (27, 62). In fact, despite the progeroid phenotype of Zmpste24
-/-
 
mice, these animals also display transcriptional alterations in metabolism regulatory genes in 
the liver and profound changes in circulating glucose and hormone levels indicative of an 
activated anti-aging response (27-29). In line with these findings, the shift in the expression 
profile of metabolic proteins found in Zmpste24
-/-
 mice highly resembles that observed in 
adipose tissue from old rats subjected to calorie restriction (18). Collectively, our proteomic 
data support the original proposal by Mariño et al. (27) that a protective metabolic response is 
triggered in Zmpste24
-/-
 mice in order to attenuate the deleterious consequences associated to 
partially processed lamin A accumulation. Despite this adaptive response, continuous 
mitochondrial overload and subsequent oxidative stress and, presumably, increased 
autophagy, would finally lead to the loss of adipose tissue observed in mutant mice.  
Metabolomic analysis revealed significant changes in plasma metabolites in Zmpste24
-
/-
 mice. These include the adrenal steroids corticosterone and aldosterone, which were up-
regulated in mutant animals. Interestingly, A-ZIP/F-1 mice, a mouse model of lipodystrophy, 
display high corticosterone serum levels, which can be partially reverted upon leptin treatment 
(63). Taking into account that circulating leptin is strongly diminished in Zmpste24
-/-
 mice 
(27), its deficiency may contribute, at least in part, to reduce the inhibitory tone on 
corticosterone secretion by the adrenal gland in these animals.  Circulating levels of the 
endocannabinoid 2-arachidonoylglycerol were highly enhanced in Zmpste24
-/-
 animals. There 
are evidences that endocannabinoids, which control food intake and energy expenditure via 
central actions and are also produced by fat cells and regulate adipose tissue metabolism, are 
increased in plasma and adipose tissue of obese rodents and human (64). Our present findings 
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support the view that, as in conditions of excess of body fat, the endogenous endocannabinoid 
system is also dysregulated in conditions of adipose tissue deficiency. Finally, mutant mice 
also exhibited a strong down-regulation of different species of the phosphatidylcholine 
derivate LPC, and both anti-inflammatory (65-66) and pro-inflammatory (67) properties have 
been attributed for LPCs. Irrespectively of their function, LPCs are increased in obese rats 
(68) and human (69). Considering the observed LPC depletion in lipoatrophic mice, LPC may 
therefore constitute a new marker of adipose tissue dysfunction. 
In summary, proteomic analysis of adipose tissue from Zmpste24
-/-
 mice and 
measurement of several metabolites in both adipose tissue and serum has enabled us to 
identify the changes in the protein expression profile and metabolic state associated with 
lipodystrophy. Our results shed new light on the importance of mitochondrial function for the 
development of lipodystrophy and for the aging process and link the accumulation of a 
partially mature form of lamin A to the dysregulation of lipid metabolism and oxidative stress 
in adipocytes. This, together with our novel findings on the regulation of HMGB1 expression 
and vimentin processing by Zmpste24, may be useful to unveil the mechanisms underlying 
adipose tissue dysfunction in laminopathies and other lipodystrophic syndromes as well as to 
develop novel strategies that may help to prevent or ameliorate these diseases. 
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FIGURE LEGENDS 
Figure 1. Maturation of the lamin A precursor (prelamin A) requires several posttranslational 
processing steps: farnesylation of the C-terminal CaaX motif, proteolysis of the C-terminal 
aaX residues by endoproteases Zmpste24 and/or Rce1, carboxymethylation of the 
farnesylated cysteine and endoproteolysis of the 15 C-terminal amino acids by Zmpste24.  
 
Figure 2. Lipoatrophy of visceral adipose tissue in Zmpste24
-/-
 mice. A) Representative 
images showing adipose tissue distribution in 4-month-old Zmpste24
+/+ 
and Zmpste24
-/-
 male 
mice. Loss of adipose tissue is evident in Zmpste24
-/-
 mice (adipose tissue is indicated by a 
red line). B) Visceral adipose tissue removed from Zmpste24
+/+ 
and Zmpste24
-/- 
animals. C) 
Comparisons of haematoxylin and eosin-stained cross sections of adipose tissue of 
Zmpste24
+/+ 
and
 
Zmpste24
-/-
 mice, showing the decreased size of adipocytes in Zmpste24-
deficient mice. T, testis; AT, adipose tissue. 
 
Figure 3. A) 2D-PAGE of whole adipose tissue of Zmpste24
+/+ 
and Zmpste24
-/-
 mice.  
Proteins were separated on a 2-DE gel using 18 cm pH 3-10 NL strips in the first dimension 
and 12% SDS-PAGE gels in the second dimension. Molecular weights are indicated (right). 
Differentially expressed proteins between the adipose tissue samples are indicated with white 
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or black arrows. The numbers correspond to the spot numbers in Table 1. B) Magnification of 
the boxed region that contains protein pyruvate dehydrogenase β (quantified in middle graph) 
in 2D-PAGE gels corresponding to four Zmpste24
+/+ 
and four Zmpste24
-/-
 mice. * P < 0.05.  
 
Figure 4. Prelamin A accumulation in Zmpste24
-/-
 mice. A) Accumulation of partially 
processed lamin A in Zmpste24-null mice could be observed in both bi-dimensional gels (pH: 
3-10) and immunoblots (lower panel). B and C) Analysis of accumulated prelamin A by 
MALDI-TOF revealed that it corresponded to the methylated form of this protein (B), which 
does not carry the C-terminal aaX amino acids, as observed by MALDI–TOF analysis of the 
C-terminal tryptic peptides corresponding to the identified forms of prelamin A (1 and 2; C). 
A totally unprocessed form of prelamin A was not detected. Farn, Farnesylated; CM, 
Carboxymethylated. 
 
Figure 5. Protein abundance (by Western blot) of malic enzyme (ME1; A), peroxiredoxin 3 
(PRDX3; B), high-mobility group box-1 protein (HMGB1; C) and phosphoenolpyruvate 
carboxykinase 1 (PCK1; D) in adipose tissue from Zmpste24
+/+
 (n=6) and Zmpste24
-/- 
(n=4) 
mice. * P < 0.05, (±S.E.M.).  
 
Figure 6. A) Magnification of a representative 2D-PAGE gel from Zmpste24
+/+
 and 
Zmpste24
-/- 
 animals showing the area of the gel containing the 4 identified isoforms of 
vimentin (53, 49, 46 and 43 kDa approximately, left panel). All the isoforms were identified 
by western blot using the vimentin antibody (right panel). Two of the identified isoforms 
showed significant expression differences between the two groups of animals when evaluated 
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by western blot (B). C) Predicted molecular weight and isoelectric point of the identified 
forms of vimentin on the basis of MALDI-TOF identification. 
 
Figure 7. Western blot for carnitine palmitoyltransferase I (CPT1; A) and uncoupling protein 
1 (UCP1; B) in adipose tissue extracts. C) Analysis of ROS levels measured as relative 
fluorescence units (RFU) of DCF-DA, per ug of protein and minute. Zmpste24
+/+
 (n=6) and 
Zmpste24
-/- 
(n=4) mice * P < 0.05, (± S.E.M.). 
 
Figure 8. A) Phosphoproteomic analysis of adipose tissue from
 
Zmpste24
+/+
 and Zmpste24
-/-  
mice. B) The phospho-peptides identified by MALDI-TOF are indicated in the table. Potential 
phosphorylation sites are underlined. C: Carbamidomethyl. M_OX: Methionine Oxidated  
 
Figure 9. Metabolic pathway analysis of the serum metabolomics experiments allowed for the 
identification of one statistically significant interaction map corresponding to free radical 
scavenging, lipid metabolism and small molecule biochemistry (top). 9 of the identified 
metabolites were identified to belong to this pathway (bottom).  
 
Figure 10. Schematic representation of the metabolic pathways altered in adipose tissue of 
Zmpste24
-/- 
mice. Up-regulated (blue) and down-regulated (green) proteins are highlighted. 
Proteins with more than a 3-fold increase between wild type and null mice are indicated with 
a double arrow. 
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 Table 1 A. Proteins identified by MALDI-TOF/TOF up-regulated in ZMPSTE24-/- 
Spot 
Num.a  
 
Protein name 
 
Symbol 
Accesion 
numberb 
MW 
(kDa)/pI 
% 
Cover.c 
Pep. 
d 
Protein 
E-value e 
Mean 
fold 
changef  
P 
Student´s 
t-test g 
1 Fatty acid synthase FAS  CH466558 276.7/6.2 12 25 44 3,61 0.002 
2 Pyruvate carboxylase PC EDL33053 130.3/6.2 48 46 118 2,51 0.001 
3 ATP citrate lyase h ACLY NP_598798 120.5/7.3 40 43 102 2,80 0002 
4 Mitochondrial inner  
membrane protein   
IMMT NP_083949 84.2/6.2  36 30 33 1,96 0.037 
5 Aconitase 2, 
mitochondrial 
ACO2 NP_542364 86.3/8.1 50 37 116 2,38 0.003 
6 Lamin A, precursor PRELA-
MIN 
NP_733821 74.5/6.5 46 30 66 > 10  
7 Acyl-CoA synthetase 
long-chain family 
member 1 
ACSL1 NP_032007 78.9/6.8 42 27 83 1,88 0.044 
8 Propionyl CoA-
carboxylase alpha-
subunit 
PCCA AAL02364 80.2/7.0 56 37 100 1,98 0.013 
9 Glycerol-3-phosphate 
dehydrogenase, mit. 
precursor (GPD-M) 
GPD2 Q64521 81.4/6.2 55 41 92 2,54 0.001 
10 Succinate 
dehydrogenase 
SDHA NP_075770 73.62/7.1   48 14 15 1,62 0.048 
11 Transketolase TKT NP_033414 68.3/7.2 63 34 139 1,77 0.010 
12 Malic enzyme 1, NADP 
(+)-dependent, cytosolic 
ME1 NP_032641 64.5/7.2 62 33 159 2,34 0.022 
13 Glucose-6-phosphate 1-
dehydrogenase 
G6PD NP_032088 59.7/ 6.1 55 40 112 1,64 0.008 
14 Mitochondrial aldehyde 
dehydrogenase 2 
ALDH2 EDL19719 55.2/8.3    54 28 159 1,71 0.005 
15 Desnutrin h ATGL AAU33824 54.4/6.0 34 22 37 1,79 0.036 
16 mCG3880 [similar to Al-
dehyde dehydrogenase 
family 3 member B1] 
 EDL32976 52.7/6.2 32 19 36 1,44 0.050 
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17 Pyruvate dehydrogenase 
protein X 
PDHX NP_780303 54.2/7.6 35 19 31 1,79 0.020 
18 Atp5b protein ATP5B AAH37127 56.7/5.2 64 25 112 1,40 0.018 
19 Ubiquinol-cytochrome c 
reductase core protein 1  
UQCRC1 NP_079683 53.3/5.7 48 21 86 1,84 0.039 
20 2-Oxoglutarate 
dehydrogenase complex 
component E2 
DLST Q01205 49.2/8.9 38 19 37 3,55 0.002 
21 Enolase 1, alpha non-
neuron 
ENO1 AAH03891 47.5/6.2 80 24 116 1,35 0.003 
22 Succinyl-CoA ligase 
[GDP-forming] subunit 
beta 
SUCLG2 NP_035637  47.1/6.6 39 16 60 1,78 0.035 
23 Acyl-Coenzyme A 
dehydrogenase, 
Short/branched chain 
ACADS AAH54428 48.3/8.0 33 19 56 2,25 0.001 
24 NADH dehydrogenase 
(ubiquinone) 1 alpha 
subcomplex 10h 
NDUFA10 NP_077159 40.1/6.4 37 23 62 2,19 0.025 
25 Acyl-CoA thioesterase 2, 
mitochondrial precursor 
ACOT2 Q9QYR9 49.8/6.9 52 19 48 2,15 0.006 
26 Citrate synthase, 
mitochondrial precursor 
CS NP_080720                 51.9/8.7 31 18 42 2,23 0.009 
27 Glutamate-ammonia 
ligase 
GLUL AAA17989  42.8 /6.6 54 23  39 1,64 0.010 
28 Isocitrate dehydrogena-
se 3 (NAD+) alpha,  
IDH3B EDL25822 35.0/5.9 62 25 96 1,68 0.001 
29 3-hydroxyisobutyryl-
Coenzyme A hydrolase 
HIBCH EDK99981 43.34/8.2 59 24 60 1,63 0.050 
30 Transaldolase 1  TALDO1 EDL18063 31.7/7.7 62 19 61 3,27 0.004 
31 Pyruvate dehydrogenase 
(lipoamide) beta 
PDHB NP_077183 39.2/6.4 63 18 69 2,56 0.005 
32 Branched-chain-   
amino-acid 
aminotransferase,mit. 
             BCATm NP_033867                 44.7/8.6 40 16 59 3,20 0.035 
33 Glycerol-3-phosphate 
dehydrogenase 
GPD1 AAA37726 38.2/6.7 68 26 68 1,74 0.009 
34 Malate dehydrogenase, 
cytoplasmic 
MDH1 NP_032644                 36.6/6.2  38 13 89 1,41 0.011 
35 3-hydroxyisobutyrate 
dehydrogenase 
HIBADH BAF42049 35.89/8.9 45 17 63 1,68 0.028 
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36 High mobility group box 
1  
HMGB1 NP_034569 24.8/6.4 57 16 47 1,87 0.023 
37 Peroxiredoxin 3 PRDX3 NP_031478 28.3/7.1 31  11 104 1,45 0.009 
 
a
 Spot numbers correspond to those on Fig. 3A, right panel. 
b Accession number from the NCBInr database. 
c
 Coverage of all peptide sequences matched to the identified protein sequence (%). 
d Pep. corresponds to the number of peptides identified (Mascot). 
e
 X!Tandem E-value after reverse database search [Data represented as –Log(E-value]. 
f Mean fold change indicates the average volume ratio of 4 Zmpste24+/+  and 4 Zmpste24-
/- animals.  
g Only those proteins with a P < 0.05 (Student’s t-test) were considered. 
h Phosphorylated proteins also detected by ProQ-Diamond Staining. 
 
Table 1B. Proteins identified by MALDI-TOF/TOF down-regulated in ZMPSTE24-/- 
 
Spot 
Num.
a  
 
Protein name 
 
Symbol 
Accesion 
numberb 
MW 
(kDa)/pI 
% 
Cover.
c 
Pep. 
d 
Protein 
E-value 
e 
Mean 
fold 
changef  
P 
Student´s 
t-test g 
1 Gelsolin precursor    GELSOLIN NP_666232                 86.3/5.83 35 20 31 1,69 0.007 
2 Phosphoenolpyruva
te carboxykinase 1, 
cytosolic 
PECK AAH37629 70.1/6.18 33 23 71 1,54 0.042 
3 Vimentin VIM NP_035831 51.6/5.0 61 34 100 1,41 0.004 
4 Alpha-1-antitrypsin SERPIN 
1A 
AAH10988  47.3/5.2 41 17 47 1,55 0.014 
5 Phosphoglycerate 
dehydrogenase 
PHGDH NP_058662 57.3/6.3 26 26 81 1,70 0.001 
6 Vimentin VIM NP_035831 53.7/5.1 
Observed 
(≈49 ) 
66 33 107 1,88 0.067 
7 Vimentin VIM NP_035831 53.7/5.1 
Observed 
(≈46 ) 
65  32 85 3,34 0.01 
8 Vimentin VIM NP_035831 53.7/5.1 
Observed 
(≈43 ) 
 64 36 103 5,55 0.009 
9 Alpha-2-
macroglobulin 35 
kDa subunit, 
precursor 
A2M Q61838 167.1/ 6.2 43 15 33 1,70 0.01 
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Fig. 3. 
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Fig. 4.  
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Fig. 5. 
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Fig. 6.  
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Fig. 8 
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1) ACLY-1 Not Determined
2) PGM-1                             108-130 AIGGIILTASHNPGGPNGDFGIK,                                0.0207. 
86-105 LVIGQNGILSTPAVSCIIRK,                                           0.0068 (C)[8]. 
3) Desnutrin                       444-462 QLLLGLFCTNVAFPPDALR,                                       -0.001 (C)[8]. 
4) Desmin                           38 52 AGFGTKGSSSSMTSR 0.059 (M_OX)[12]
5) PDHA1                                         Not Determined
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Fig. 9.  
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Fig.10. 
 
 
 
 
